Showing 2841-2850 of 5621 results for "".
- CooperVision Releases Four-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-four-year-data-on-landmark-misight-1-day-contact-lens-study/2479840/New 4-year study data shows the significant impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later. CooperVision recently presented the multi-year study’s latest outcomes during the
- Hoya Launches 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-launches-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2479847/Hoya Surgical Optics officially launched the new multiSert 4-in-1 preloaded delivery system with Vivinex IOL at the European Society of Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria. “MultiSert is
- SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Painhttps://modernod.com/news/siteone-therapeutics-receives-nih-grant-to-support-the-development-of-novel-therapeutics-to-treat-ocular-pain/2479849/SiteOne Therapeutics announced that the company has been awarded a $1.4 million, 2-year, phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for Site
- OD-OS to Celebrate 10 Years of the Navilas Laser Systems at EURETINAhttps://modernod.com/news/od-os-to-celebrate-10-years-of-the-navilas-laser-systems-at-euretina/2479864/OD-OS, the inventor of the Navilas laser systems, is celebrating 10 years of retina navigation with expert sessions at the upcoming EURETINA 2018 conference in Vienna, September 21-25, booth C207. <
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- CooperVision Releases 4-Year Data on Landmark MiSight 1-Day Contact Lens Studyhttps://modernod.com/news/coopervision-releases-4-year-data-on-landmark-misight-1-day-contact-lens-study/2479874/New 4-year study data shows the the impact of a pioneering contact lens management approach to slowing the progression of myopia in children, including those whose treatment begins later, according to a CooperVision news release. CooperVision is presenting the multi-year study’s latest out
- LumiThera to Debut Valeda Light Delivery System at EURETINAhttps://modernod.com/news/lumithera-to-debut-valeda-light-delivery-system-at-euretina/2479887/LumiThera announced that it will debut the Valeda Light Delivery System for the treatment of dry AMD in the exhibition hall at the EURETINA meeting in Vienna. It will also host a symposium on photobiomodulation (PBM) technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targ
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- UK Calls on Drugmakers to Stockpile 6-Week Supply of Medicines to Cope With “No Deal” Brexithttps://modernod.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/The UK’s Department of Health and Social Care has asked pharmaceutical companies that supply drugs to NHS patients to “ensure they have a minimum of six weeks additional supply” of medicines, over and above their usual buffer stocks, in case imports from the EU are disrupted in
- Open-Angle Glaucoma in One Eye Likely to Develop in the Otherhttps://modernod.com/news/open-angle-glaucoma-in-one-eye-likely-to-develop-in-the-other/2479915/Patients with open-angle glaucoma in one eye are at increased risk for developing glaucoma in the second eye, researchers report, according to Reuters Health. “Among patients with newly diagnosed open-angle glaucoma, almost ha